Compare DELL & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DELL | NVO |
|---|---|---|
| Founded | 1984 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.7B | 197.4B |
| IPO Year | 2013 | N/A |
| Metric | DELL | NVO |
|---|---|---|
| Price | $395.57 | $43.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 11 |
| Target Price | ★ $181.63 | $51.00 |
| AVG Volume (30 Days) | 9.6M | ★ 11.3M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | 1.23% | ★ 3.19% |
| EPS Growth | ★ 36.05 | N/A |
| EPS | ★ 5.24 | N/A |
| Revenue | ★ $113,538,000,000.00 | N/A |
| Revenue This Year | $26.19 | N/A |
| Revenue Next Year | $8.60 | $3.70 |
| P/E Ratio | $74.75 | ★ $13.60 |
| Revenue Growth | ★ 18.80 | N/A |
| 52 Week Low | $110.22 | $35.12 |
| 52 Week High | $469.47 | $71.80 |
| Indicator | DELL | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 52.92 |
| Support Level | $126.13 | $43.35 |
| Resistance Level | $469.47 | $46.05 |
| Average True Range (ATR) | 27.72 | 1.37 |
| MACD | -2.74 | -0.18 |
| Stochastic Oscillator | 57.91 | 61.34 |
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners and also relies heavily on channel partners to fulfill its sales.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.